SynAct Pharma ABOSTO:SYNACT +0.92%18 Market Cap is kr864.61 Mil as of Jun. 29, 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, SynAct Pharma AB ranks worse than 53.43% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SynAct Pharma AB's share price for the quarter that ended in Mar. 2026 was kr18.28. SynAct Pharma AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 56.00 Mil. Therefore, SynAct Pharma AB's market cap for the quarter that ended in Mar. 2026 was kr1,023.64 Mil.
SynAct Pharma AB's quarterly market cap
increased
from Sep. 2025 (kr1,191.93 Mil) to Dec. 2025 (kr1,205.26 Mil) but then
declined
from Dec. 2025 (kr1,205.26 Mil) to Mar. 2026 (kr1,023.64 Mil).
SynAct Pharma AB's annual market cap
increased
from Dec. 2023 (kr314.09 Mil) to Dec. 2024 (kr416.76 Mil) and
increased
from Dec. 2024 (kr416.76 Mil) to Dec. 2025 (kr1,205.26 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SynAct Pharma AB's Enterprise Value for Today is kr799.90 Mil.
SynAct Pharma AB (OSTO:SYNACT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SynAct Pharma AB Market Cap Related Terms
SynAct Pharma AB Market Cap Historical Data
* Premium members only.
The historical data trend for SynAct Pharma AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SYNACT vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, SynAct Pharma AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynAct Pharma AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Market Cap distribution charts can be found below:
* The bar in red indicates where SynAct Pharma AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SynAct Pharma AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynAct Pharma AB (OSTO:SYNACT) has a Market Cap of kr864.61 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SynAct Pharma AB and its competitors. According to the industry distribution chart, SynAct Pharma AB ranks #763 out of 1428 companies in the Biotechnology industry, placing it in the top 53.4%.
Is SynAct Pharma AB's Market Cap too high?
SynAct Pharma AB's current Market Cap is kr864.61 Mil. Based on the distribution chart, SynAct Pharma AB ranks #763 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynAct Pharma AB ranks #763 out of 1428 companies for Market Cap. This places SynAct Pharma AB in the lower half of its industry. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SynAct Pharma AB and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SynAct Pharma AB's current Market Cap is kr864.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Market Cap of kr864.61 Mil. The current Market Cap is kr864.61 Mil. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Market Cap is kr864.61 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score
Get the complete analysis for OSTO:SYNACT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNACT has been successfully added to your 
